Please wait while we load the requested 10-K report or click the link below:
FOR IMMEDIATE RELEASE
Harvard Apparatus Regenerative Technology Reports Operating Results for the Fourth Quarter and Year Ended December 31, 2014
-Conference Call To Be Held at 11:00 AM ET Today-
Holliston, MA, March 19, 2015- Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), or HART, a clinical stage biotechnology company developing regenerated organs for transplant, initially focused on the trachea, reports unaudited financial results for the three months and year ended December 31, 2014.
David Green, President and CEO of Harvard Apparatus Regenerative Technology, commented, “ During the full year of 2014, and more recently, we made significant progress on critical aspects of making regenerated organs for transplant a reality for patients. Highlights include:
|·||The 5th adult patient was transplanted with a HART-Trachea.|
|·||Average survival among the 5 patients has been 22 months which is a significant improvement over the prognosis at the time of transplant which was typically just a few months. Of the three patients who have died, none of them died because of a failure of our scaffold. Two of the patients are still alive. One is at approximately 9 months and one at approximately two and a half years from transplant.|
|·||We received orphan status in the U.S. This will give us 7 years of exclusivity in the U.S. from the date of launch of the HART-Trachea.|
|·||We have moved away from Russian clinical studies towards US clinical studies, in particular with our collaboration agreement with Mayo Clinic, one of the world’s leading hospitals.|
The following information was filed by Biostage, Inc. (BSTG) on Thursday, March 19, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Biostage, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Biostage, Inc..